AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19201650 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily) and bevacizumab (15 mg/kg every 3 weeks)
Number of subjects: 48
Study 19201650 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib and bevacizumab
Number of subjects: 48
Study 17429343 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line hemofiltration
Number of subjects: 15
Study 17429343 — intervention group
Group type: COMPARATOR
Intervention: High-flux hemodialysis (HF-HD)
Number of subjects: 15
Study 15075311 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral resistance training (training intensities of at least 50% of maximal voluntary strength for a minimum of 2 weeks)
Number of subjects: 17
Study 15075311 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral resistance training
Number of subjects: 17
Study 11269613 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef protein (43 g for women and 50 g for men daily)
Number of subjects: 23
Study 11269613 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant protein (equal amount of protein from legumes, nuts, and grains)
Number of subjects: 23
Study 11269613 — intervention group
Group type: COMPARATOR
Intervention: Self-selected prestudy diets
Number of subjects: 23
Study 9464712 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (60 g daily containing 40 g of isolated soy protein)
Number of subjects: 104
Study 9464712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (casein, 60 g daily)
Number of subjects: 104
Study 7646157 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tissue cardiac valve implantation
Number of subjects: 30
Study 7646157 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic examination
Number of subjects: 30
Study 2654791 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT (amsacrine, cytarabine, thioguanine)
Number of subjects: 69
Study 2654791 — intervention group
Group type: COMPARATOR
Intervention: DAT (daunorubicin, cytarabine, thioguanine)
Number of subjects: 69
Study 794897 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg daily)
Number of subjects: 0
Study 794897 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (8 g daily)
Number of subjects: 0
Study 30537411 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise training (CONT; n = 17; 70% of peak heart rate)
Number of subjects: 31
Study 30537411 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise training (INT; n = 14; 3 min at 50% of peak heart rate and 3 min at 90% of peak heart rate)
Number of subjects: 31
Study 30537411 — intervention group
Group type: COMPARATOR
Intervention: Both CONT and INT training
Number of subjects: 31
Study 30537411 — intervention group
Group type: COMPARATOR
Intervention: Exercise dose (kilocalories per session)
Number of subjects: 31
Study 28295869 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT programmed on (CRT-on)
Number of subjects: 1591
Study 28295869 — intervention group
Group type: COMPARATOR
Intervention: CRT programmed off (CRT-off)
Number of subjects: 1591
Study 25185469 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based coaching by a surgeon using the GROW coaching model
Number of subjects: 20
Study 25185469 — intervention group
Group type: COMPARATOR
Intervention: Control group viewing online surgical lectures
Number of subjects: 20
Study 25185469 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based coaching
Number of subjects: 20
Study 23558043 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine (5 mg twice daily)
Number of subjects: 46
Study 23558043 — intervention group
Group type: EXPERIMENTAL
Intervention: ranolazine (375 mg twice daily)
Number of subjects: 46
Study 23558043 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study 22010346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangshen Formula
Number of subjects: 0
Study 22010346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangshen Formula + Conventional western medicine
Number of subjects: 0
Study 22010346 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine
Number of subjects: 0
Study 19828704 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 356
Study 19828704 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 356
Study 19828704 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched sibling donor
Number of subjects: 356
Study 19828704 — intervention group
Group type: COMPARATOR
Intervention: No matched sibling donor
Number of subjects: 356
Study 19828704 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsed patients
Number of subjects: 356
Study 19828704 — intervention group
Group type: COMPARATOR
Intervention: Complex cytogenetic abnormalities
Number of subjects: 356
Study 19828704 — intervention group
Group type: COMPARATOR
Intervention: CNS involvement at diagnosis
Number of subjects: 356
Study 19828704 — intervention group
Group type: EXPERIMENTAL
Intervention: CD1a positivity
Number of subjects: 356
Study 19828704 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of CD13 expression
Number of subjects: 356
Study 19828704 — intervention group
Group type: EXPERIMENTAL
Intervention: NOTCH1 mutations
Number of subjects: 356
Study 19828704 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKN2A mutations
Number of subjects: 356
Study 16914703 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg)
Number of subjects: 201
Study 16914703 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (1 microg)
Number of subjects: 201
Study 14999637 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (800 mg every day)
Number of subjects: 0
Study 14999637 — intervention group
Group type: COMPARATOR
Intervention: Oxandrolone (10 mg twice per day)
Number of subjects: 0
Study 11824370 — intervention group
Group type: EXPERIMENTAL
Intervention: Local and systemic application of growth factors
Number of subjects: 0
Study 11824370 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental research on growth factors
Number of subjects: 0
Study 9238874 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2 dentifrice (Crest Plus Gum Care)
Number of subjects: 0
Study 9238874 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Listerine)
Number of subjects: 0
Study 9238874 — intervention group
Group type: COMPARATOR
Intervention: NaF dentifrice (Crest)
Number of subjects: 0
Study 9238874 — intervention group
Group type: COMPARATOR
Intervention: Baking soda/peroxide dentifrice (Mentadent)
Number of subjects: 0
Study 8491302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8491302 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg terbutaline
Number of subjects: 17
Study 8491302 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg terbutaline
Number of subjects: 17
Study 8491302 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg terbutaline
Number of subjects: 17
Study 8491302 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of terbutaline (2, 4, 6 mg)
Number of subjects: 17
Study 6366126 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin (or ticarcillin) plus amikacin
Number of subjects: 841
Study 6366126 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin (or ticarcillin) plus amikacin plus cefazolin
Number of subjects: 841
Study 6366126 — intervention group
Group type: EXPERIMENTAL
Intervention: Any oral intestine decontamination regimen
Number of subjects: 841
Study 31787506 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 221
Study 31787506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 28206715 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First
Number of subjects: 470
Study 28206715 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 470
Study 27005498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low lactose milk powder feeding in treatment group (64 cases)
Number of subjects: 311
Study 27005498 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (rehydration, correction of acidosis, oral smecta, intestinal probiotics) in control group (60 cases)
Number of subjects: 311
Study 27005498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low lactose milk powder feeding in treatment group
Number of subjects: 311
Study 27005498 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in control group
Number of subjects: 311
Study 25102239 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and double leg drop jumps from a range of heights that equalized loading per leg.
Number of subjects: 14
Study 25102239 — intervention group
Group type: EXPERIMENTAL
Intervention: Equalizing loading by impulse per leg.
Number of subjects: 14
Study 25102239 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minute coaching session for consistent drop height.
Number of subjects: 14
Study 22033742 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty reduction intervention (IC)
Number of subjects: 665
Study 22033742 — intervention group
Group type: COMPARATOR
Intervention: Usual care clinics (UCC)
Number of subjects: 665
Study 20073409 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of daily OxyContin
Number of subjects: 36
Study 20073409 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg of daily OxyContin
Number of subjects: 36
Study 20073409 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg of daily OxyContin
Number of subjects: 36
Study 20073409 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized values using the algorithm
Number of subjects: 36
Study 16765063 — intervention group
Group type: EXPERIMENTAL
Intervention: Posthypnotic suggestion to perceive input stream as meaningless symbols
Number of subjects: 0
Study 16765063 — intervention group
Group type: COMPARATOR
Intervention: No posthypnotic suggestion
Number of subjects: 0
Study 16962929 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 14 days
Number of subjects: 30
Study 16962929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14982753 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe diabetes (SD)
Number of subjects: 28
Study 14982753 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild diabetes (MD)
Number of subjects: 28
Study 14982753 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic (ND)
Number of subjects: 28
Study 11310245 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Buckley's Formocresol
Number of subjects: 52
Study 11310245 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide
Number of subjects: 52
Study 11310245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (F and C)
Number of subjects: 52
Study 8548465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix 320; 40 to 240 mL, mean 141 mL)
Number of subjects: 48
Study 8548465 — intervention group
Group type: COMPARATOR
Intervention: Ioversol (Optiray 320; 20 to 180 mL, mean 87 mL)
Number of subjects: 48
Study 1808526 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injections with Depo‐Medrol or Polcortolon plus bupivacaine
Number of subjects: 30
Study 1808526 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injections with Polcortolon plus bupivacaine
Number of subjects: 30
Study 1808526 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 30
Study 6419595 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 209
Study 6419595 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate
Number of subjects: 209
Study 6419595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 31778446 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg/day for 16 weeks
Number of subjects: 39
Study 31778446 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral isotretinoin 0.3-0.4 mg/kg for 16 weeks
Number of subjects: 39
Study 30327236 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy
Number of subjects: 107
Study 30327236 — intervention group
Group type: COMPARATOR
Intervention: Sequential or radiotherapy alone
Number of subjects: 107
Study 30327236 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 107
Study 28807086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids followed by intranasal steroids (Group A)
Number of subjects: 290
Study 28807086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids alone (Group B)
Number of subjects: 290
Study 28807086 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (Group C)
Number of subjects: 290
Study 28807086 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 290
Study 25870079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 759
Study 25870079 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 759
Study 24229669 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin therapy (including a single injection of basal insulin and basal insulin plus preprandial insulin)
Number of subjects: 1086
Study 24229669 — intervention group
Group type: COMPARATOR
Intervention: Premixed insulin therapy
Number of subjects: 1086
Study 20642328 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group participation (12 monthly support group meetings)
Number of subjects: 49
Study 20642328 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group participation
Number of subjects: 49
Study 20642328 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 49
Study 19542400 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose unenhanced CT
Number of subjects: 207
Study 19542400 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose i.v. contrast-enhanced CT
Number of subjects: 207
Study 16942934 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with the most common genotype combination of SNPs (‐604G/A, ‐501A/C, Leu72Met, Gln90Leu)
Number of subjects: 522
Study 15501741 — intervention group
Group type: EXPERIMENTAL
Intervention: Valium (0.1 mg/kg)
Number of subjects: 240
Study 15501741 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (50 mg/kg)
Number of subjects: 240
Study 15501741 — intervention group
Group type: EXPERIMENTAL
Intervention: Valium (0.1 mg/kg) and Magnesium sulfate (50 mg/kg)
Number of subjects: 240
Study 15501741 — intervention group
Group type: COMPARATOR
Intervention: Control (neither valium nor magnesium sulfate)
Number of subjects: 240
Study 10785910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training group
Number of subjects: 86
Study 10785910 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise group
Number of subjects: 86
Study 10785910 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 9366103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg/hydrochlorothiazide 12.5 mg
Number of subjects: 188
Study 9366103 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg/hydrochlorothiazide 25 mg
Number of subjects: 188
Study 8222202 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein (SV) coronary grafts
Number of subjects: 349
Study 2931040 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol metered-dose inhaler
Number of subjects: 30
Study 2931040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30809776 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh red blood cells (7 days or less)
Number of subjects: 217
Study 30809776 — intervention group
Group type: COMPARATOR
Intervention: Standard red blood cells
Number of subjects: 217
Study 30809776 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh red blood cells
Number of subjects: 217
Study 29749935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion-optimized intervals (FOI)
Number of subjects: 180
Study 29749935 — intervention group
Group type: COMPARATOR
Intervention: Nominal settings
Number of subjects: 180
Study 26930241 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session DV prevention program (active condition)
Number of subjects: 225
Study 26930241 — intervention group
Group type: COMPARATOR
Intervention: Health class as usual (waitlist control condition)
Number of subjects: 225
Study 25300431 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 34
Study 25300431 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 34
Study 22624978 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula
Number of subjects: 0
Study 22624978 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially whey hydrolyzed formula
Number of subjects: 0
Study 22624978 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed whey formula
Number of subjects: 0
Study 19910797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 0
Study 18929702 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridine therapy continued beyond 1 year
Number of subjects: 2736
Study 18929702 — intervention group
Group type: COMPARATOR
Intervention: Thienopyridine therapy discontinued after 1 year
Number of subjects: 2736
Study 16385904 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic candidates
Number of subjects: 0
Study 16385904 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified method by Chow and Shao (1997)
Number of subjects: 0
Study 16385904 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study 11431603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal insulin administration (gelified form)
Number of subjects: 16
Study 11431603 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous regular insulin injections
Number of subjects: 16
Study 9876229 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA stimulation
Number of subjects: 56
Study 9876229 — intervention group
Group type: EXPERIMENTAL
Intervention: ZX stimulation
Number of subjects: 56
Study 9876229 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting cells
Number of subjects: 56
Study 9876229 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA and ZX stimulation
Number of subjects: 56
Study 9876229 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of interleukin-6
Number of subjects: 56
Study 8027276 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin acetate (nasal spray)
Number of subjects: 0
Study 8027276 — intervention group
Group type: COMPARATOR
Intervention: Buserelin acetate (nasal spray)
Number of subjects: 0
Study 8027276 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin acetate
Number of subjects: 0
Study 8027276 — intervention group
Group type: COMPARATOR
Intervention: Buserelin acetate
Number of subjects: 0
Study 2513939 — intervention group
Group type: EXPERIMENTAL
Intervention: Three days' treatment with co-trimoxazole 960 mg twice a day
Number of subjects: 327
Study 2513939 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven days' treatment with co-trimoxazole 960 mg twice a day
Number of subjects: 327
Study 788001 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 40
Study 788001 — intervention group
Group type: COMPARATOR
Intervention: Loxapin
Number of subjects: 40
Study 31705450 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled dill seed (10 g boiled in 100 mL for 10 min, given orally at the beginning of active phase)
Number of subjects: 100
Study 31705450 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (10 IU in 1000 mL of Ringer solution)
Number of subjects: 100
Study 31705450 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled dill seed
Number of subjects: 100
Study 31705450 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 100
Study 30427243 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat training combined with 'LHTL' hypoxia (H+H; FiO2 = 14.4% [3000 m], 13 h·d‐1; train at <600 m, 33°C, 55% relative humidity [RH])
Number of subjects: 25
Study 30427243 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat training (HOT; live and train <600 m, 33°C, 55% RH)
Number of subjects: 25
Study 30427243 — intervention group
Group type: COMPARATOR
Intervention: Temperate training (CONT; live and train <600 m, 13°C, 55% RH)
Number of subjects: 25
Study 27320685 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL-only treatment
Number of subjects: 14
Study 27320685 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL + rapamycin
Number of subjects: 14
Study 27320685 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL + Erbium YAG laser ablation + rapamycin
Number of subjects: 14
Study 27320685 — intervention group
Group type: EXPERIMENTAL
Intervention: rapamycin monotherapy
Number of subjects: 14
Study 27320685 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL + Erbium YAG + rapamycin
Number of subjects: 14
Study 25399948 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened (46 weeks), intensified therapy
Number of subjects: 147
Study 23221935 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/day of encapsulated WGOE
Number of subjects: 37
Study 23221935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 21288608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learning method
Number of subjects: 34
Study 21288608 — intervention group
Group type: COMPARATOR
Intervention: Traditional learning method
Number of subjects: 34
Study 18649754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cernilton 750 mg, twice a day for 4 years
Number of subjects: 240
Study 18649754 — intervention group
Group type: COMPARATOR
Intervention: Cernilton 375 mg, twice a day for 4 years
Number of subjects: 240
Study 18649754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cernilton 750 mg
Number of subjects: 240
Study 18649754 — intervention group
Group type: COMPARATOR
Intervention: Cernilton 375 mg
Number of subjects: 240
Study 17050212 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 0
Study 17050212 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 0
Study 17050212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17050212 — intervention group
Group type: COMPARATOR
Intervention: No drugs (baseline)
Number of subjects: 0